Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Bonus BioGroup
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Agreement January 16, 2020
This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.